Research Article

Journal of Artificial Intelligence in Healthcare & Medicine

Artificial Intelligence–Driven Biological Reasoning Systems in Healthcare and Regulatory Science

Ian Jenkins[1], Krista Casazza[2], Vaishnavi Narayan[1], Waldemar Lernhardt[1], Jayson Uffens[1] and Jonathan RT Lakey[1,2*]

[1]*GATC Health Corp., Irvine, California, USA.*

[2]*Departments of Surgery and Biomedical Engineering, University of California Irvine, Irvine, California, USA.*

***Correspondence:**

Jonathan RT Lakey, PhD, MSM, Chair, Scientific Advisory Board, GATC Health Corp., Professor Emeritus, Departments of Surgery and Biomedical Engineering, University of California Irvine, Irvine, California, USA.

Received: 01 Mar 2026; **Accepted:** 03 Apr 2026; **Published:** 14 Apr 2026

Citation: Ian Jenkins, Krista Casazza, Vaishnavi Narayan, et al. Artificial Intelligence–Driven Biological Reasoning Systems in Healthcare and Regulatory Science. J Artif Intell Healthcare Med. 2026; 1(1); 1-4.

ABSTRACT

Artificial intelligence (AI) is rapidly transforming healthcare, enabling new approaches to diagnosis, treatment optimization, and drug development. Recent advances in machine learning, multi-omics data integration, and computational modeling have expanded the role of AI beyond pattern recognition toward mechanistically informed reasoning about biological systems. This review examines emerging paradigms in AI-driven healthcare, with particular emphasis on multi-modal biomedical data integration, regulatory-grade AI systems, and new computational frameworks for predicting therapeutic efficacy and safety. We discuss the limitations of traditional predictive models in biomedical applications and highlight the emergence of AI-native reasoning architectures capable of synthesizing heterogeneous biological evidence under uncertainty. Particular attention is given to applications in drug discovery, toxicology, and regulatory science, where AI platforms can generate mechanistically interpretable insights and support decision-making across complex biological domains. These developments align with the evolving mission of medical AI to bridge computational science and clinical practice by producing robust, transparent, and clinically actionable knowledge.

Keywords

Multi-omics Data Integration, Precision Medicine, Drug Discovery, Therapeutic Efficacy, Toxicology, Regulatory Science.

Introduction

Artificial intelligence (AI) has emerged as a transformative force across healthcare and biomedical research, enabling new methods for analyzing large-scale biological data and improving clinical decision-making [1-3]. The rapid expansion of digital health records, molecular datasets, imaging repositories, and biomedical literature has created an unprecedented opportunity for computational systems to identify patterns and generate predictive insights that were previously inaccessible [4]. AI-based models have demonstrated significant potential in disease diagnosis, risk stratification, and treatment personalization, contributing to improvements in patient care and healthcare delivery efficiency [5]. However, despite these advances, many AI applications in healthcare remain limited by methodological challenges that restrict their translation into clinical and regulatory settings [6]. Conventional machine learning (ML) models typically rely on statistical correlations derived from historical datasets and may lack the mechanistic transparency required for clinical interpretation or regulatory evaluation [1,7]. As healthcare systems increasingly rely on AI-generated insights to guide decisions affecting patient safety and therapeutic development, the need for interpretable, biologically grounded computational frameworks has become increasingly urgent. In response, recent healthcare and biomedical research has shifted toward AI-native reasoning systems capable of integrating heterogeneous biomedical data and representing biological processes in a mechanistically meaningful way [8]. These dynamic approaches move beyond simple predictive modeling and instead focus on constructing computational

representations of biological systems that can simulate therapeutic interventions and predict downstream effects [9]. Such therapeutic simulation systems hold particular promise for applications in drug development and regulatory science, where understanding the biological mechanisms underlying therapeutic effects and adverse events is critical.

AI in Healthcare: From Prediction to Mechanistic Reasoning

The earliest applications of AI in healthcare primarily focused on classification and prediction tasks, such as image-based disease detection or risk prediction using electronic health records [10,11]. ML algorithms, including deep neural networks and ensemble models, have demonstrated high accuracy across a range of clinical applications, including radiology, pathology, and predictive analytics. These models leverage large datasets to identify statistical relationships between input features and clinical outcomes, enabling automated or assisted decision-making in healthcare settings [12]. While these predictive systems have achieved impressive performance metrics, they often struggle when applied to complex biological problems where causal relationships are poorly understood or where training data may not fully capture the diversity of real-world biological conditions [13-15]. For example, drug safety prediction requires reasoning about molecular interactions, metabolic transformations, and biological pathway perturbations, all of which involve mechanisms that extend beyond simple statistical associations. To address these limitations, emerging research in medical AI has emphasized multi-modal learning frameworks capable of integrating diverse data modalities such as clinical records, imaging data, genomic information, and molecular profiles [16]. Integrated AI systems that combine multiple data sources have been shown to outperform single-modality models and enable more robust predictions across healthcare applications. The transition from single-modality predictive models to multi-modal reasoning systems represents a fundamental shift in the design of AI for healthcare [17]. Rather than treating biomedical data as independent variables, these frameworks model relationships among biological entities and processes, allowing AI systems to simulate biological responses and generate mechanistic hypotheses.

Multi-Omic Data Integration and Systems-Level Modeling

The integration of multi-omic datasets has become a cornerstone of modern biomedical research [18]. Advances in genomic sequencing, transcriptomics, proteomics, and metabolomics have enabled researchers to characterize biological systems with unprecedented resolution. However, the complexity of these datasets presents significant analytical challenges, as biological processes involve interactions across multiple molecular and cellular layers. AI-driven multi-omic integration approaches seek to address this challenge by constructing computational models that represent the causal relationships governing biological systems [19]. By integrating molecular datasets with curated biological knowledge, such models can simulate the behavior of complex biological networks and predict how therapeutic interventions may alter these systems [20]. In healthcare and pharmaceutical research, systems-level modeling approaches have become increasingly important for understanding disease mechanisms and therapeutic responses. AI platforms capable of modeling gene regulatory networks, signaling pathways, and metabolic interactions can generate insights into how drugs interact with biological systems and identify potential mechanisms underlying adverse drug reactions.

Multi-omic data integration approaches are particularly valuable for addressing safety challenges in drug development [21,22]. Toxicological outcomes often emerge from complex interactions among molecular pathways, metabolic processes, and physiological systems, making them difficult to predict using traditional statistical models [23,24]. AI-based systems that integrate molecular data with mechanistic pathway knowledge offer a promising pathway for predicting toxicity and identifying potential safety liabilities early in the drug development process [24]. An illustrative example of this emerging class of AI-enabled biological reasoning systems is the development of integrated computational platforms designed to simulate biological responses to therapeutic compounds by combining multi-omic data, molecular interaction networks, and pharmacologic evidence within a unified modeling framework. One such approach, the Operon™ platform [25] (GATC Health, Irvine, CA), applies AI architectures designed to preserve mechanistic relationships among genes, proteins, metabolic pathways, and disease processes while enabling cross-modal reasoning across heterogeneous biomedical datasets. By structuring biological knowledge into causal network representations and integrating it with ML–based inference, the platform seeks to generate interpretable predictions regarding therapeutic efficacy and potential safety risks. Approaches of this type exemplify how AI systems can move beyond purely statistical prediction toward mechanistically grounded simulation of biological systems, providing a potential pathway for integrating computational reasoning tools into drug development and regulatory science contexts.

AI for Regulatory Science and Drug Safety Assessment

In addition to clinical applications, AI is increasingly being explored as a tool for regulatory science. Regulatory agencies responsible for evaluating the safety and efficacy of medical products face growing challenges as therapies become more complex and biomedical data volumes continue to expand. AI systems capable of synthesizing diverse evidence sources and generating mechanistically interpretable predictions could significantly enhance regulatory decision-making processes. One promising area of research involves the use of AI to support New Approach Methodologies (NAMs) for toxicology [26] and safety assessment [27]. NAMs aim to reduce reliance on traditional animal testing by integrating computational models, in vitro experiments, and mechanistic biological knowledge to predict safety risks [28]. AI platforms capable of reasoning across chemical structure, metabolic pathways, and biological responses may enable more accurate prediction of toxicity outcomes and improve the efficiency of preclinical safety evaluation. For example,

mutagenicity assessment using the Ames test remains a critical step in evaluating the genotoxic potential of chemical compounds during drug development [29]. Traditional computational models for Ames prediction typically rely on structure-based alerts or statistical classifiers trained on historical data [30]. While useful, these approaches often struggle to generalize to novel chemical scaffolds or to incorporate complex biological context such as metabolic activation pathways. Emerging AI-native reasoning frameworks address these limitations by integrating structural, metabolic, and mechanistic information into unified models capable of generating probabilistic safety assessments. Such systems treat uncertainty as a fundamental component of prediction and enable decision-makers to evaluate confidence in predicted outcomes. This approach represents an important step toward regulatory-grade AI systems capable of supporting safety evaluation in complex biomedical contexts.

Challenges and Ethical Considerations

Despite the transformative potential of AI in healthcare, several challenges must be addressed before these technologies can be widely adopted in clinical and regulatory environments. One key concern involves algorithmic bias, which can arise when training datasets do not adequately represent diverse patient populations [31]. Bias in AI models may lead to disparities in diagnostic accuracy or treatment recommendations, highlighting the need for careful dataset curation and fairness-aware modeling approaches [32]. Another important challenge involves ensuring the trustworthiness and transparency of AI systems used in healthcare [33]. Researchers have emphasized the importance of interpretability, robustness, and traceability in AI models that influence clinical or regulatory decisions. International consensus guidelines for trustworthy AI in healthcare emphasize principles such as fairness, universality, usability, robustness, and explainability as essential components of deployable medical AI systems [34]. Addressing these challenges requires interdisciplinary collaboration among computer scientists, clinicians, regulatory scientists, and ethicists to ensure that AI technologies are developed and deployed responsibly.

Future Directions

The next generation of AI systems in healthcare will likely focus on integrating mechanistic biological knowledge with large-scale data-driven learning. Advances in generative modeling, causal inference, and network-based ML are enabling the development of AI platforms capable of reasoning about biological systems rather than simply predicting outcomes.

Such systems have the potential to revolutionize drug discovery by enabling simulation of therapeutic interventions, prediction of safety risks, and identification of optimal treatment strategies before costly clinical trials are conducted. In clinical practice, AI-enabled systems may support personalized medicine by integrating genomic information, clinical data, and environmental factors to tailor treatment strategies for individual patients. The integration of AI with systems biology and regulatory science represents a particularly promising frontier. Computational platforms capable of generating mechanistically interpretable predictions could provide regulatory agencies with new tools for evaluating emerging therapies and improving the efficiency of drug development. Platforms such as the Operon framework illustrate how future AI systems may integrate multi-omic data, mechanistic pathway knowledge, and causal network modeling to enable biologically grounded simulation of therapeutic effects and safety risks, supporting both drug development and regulatory science.

Conclusion

AI is rapidly reshaping healthcare and biomedical research, offering powerful tools for analyzing complex biological data and improving medical decision-making. While early AI systems focused primarily on predictive modeling, emerging approaches emphasize mechanistic reasoning, multi-modal data integration, and transparency in computational predictions. These developments are enabling the creation of AI platforms capable of simulating biological systems and generating insights into therapeutic safety and efficacy. As the field continues to evolve, the integration of AI with systems biology and regulatory science will play a critical role in translating computational innovation into practical healthcare applications. By developing AI systems that are interpretable, reliable, and grounded in biological mechanisms, researchers can help ensure that AI becomes a trusted and effective tool for improving patient outcomes and advancing biomedical innovation.

References

1. Fahim YA, Hasani IW, Kabba S, et al. Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives. Eur J Med Res. 2025; 30: 848.
2. Aravazhi PS, Gunasekaran P, Benjamin NZY, et al. The integration of artificial intelligence into clinical medicine: Trends, challenges, and future directions. Dis Mon. 2025; 71: 101882.
3. Chong PL, Vaigeshwari V, Mohammed RBK, et al. Integrating artificial intelligence in healthcare: applications, challenges, and future directions. Future Sci OA. 2025; 11: 2527505.
4. Yang A, Pan ML, Lu HHS, et al. Assessing the Evolution and Influence of Medical Open Databases on Biomedical Research and Health Care Innovation: A 25-Year Perspective with a Focus on Privacy and Privacy-Enhancing Technologies. J Med Internet Res. 2026; 28: e58954.
5. Dixon D, Sattar H, Moros N, et al. Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review. Cureus. 2024; 16: e59954.
6. Mohajer-Bastami A, Moin S, Ahmad S, et al. Artificial intelligence in healthcare: applications, challenges, and future directions. A narrative review informed by international, multidisciplinary expertise. Front Digit Health. 2025; 7: 1644041.
7. Ennab M, Mcheick H. Enhancing interpretability and

accuracy of AI models in healthcare: a comprehensive review on challenges and future directions. Front Robot AI. 2024; 11: 1444763.

8. Parvin N, Joo SW, Jung JH, et al. Multimodal AI in Biomedicine: Pioneering the Future of Biomaterials, Diagnostics, and Personalized Healthcare. Nanomaterials. 2025; 15: 895.
9. Wang X, Xie H. An intelligent framework for dynamic modeling of therapeutic response using clinical compliance data. Front Pharmacol. 2025; 16: 1631599.
10. Bajwa J, Munir U, Nori A, et al. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021; 8: e188-e194.
11. Bohr A, Memarzadeh K. The rise of artificial intelligence in healthcare applications. Artif Intell Healthc. 2020; 25-60.
12. Obuchowicz R, Strzelecki M, Piórkowski A. Clinical Applications of Artificial Intelligence in Medical Imaging and Image Processing-A Review. Cancers. 2024; 16: 1870.
13. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023; 23: 689.
14. Sharma A, Lysenko A, Jia S, et al. Advances in AI and machine learning for predictive medicine. J Hum Genet. 2024; 69: 487-497.
15. Sadr H, Nazari M, Khodaverdian Z, et al. Unveiling the potential of artificial intelligence in revolutionizing disease diagnosis and prediction: a comprehensive review of machine learning and deep learning approaches. Eur J Med Res. 2025; 30: 418.
16. Khan SN, Danishuddin, Khan MWA, et al. Multi-modal AI in precision medicine: integrating genomics, imaging, and EHR data for clinical insights. Front Artif Intell. 2025; 8: 1743921.
17. Soenksen LR, Ma Y, Zeng C, et al. Integrated multimodal artificial intelligence framework for healthcare applications. NPJ Digit Med. 2022; 5: 149.
18. Morabito A, De Simone G, Pastorelli R, et al. Algorithms and tools for data-driven omics integration to achieve multilayer biological insights: a narrative review. J Transl Med. 2025; 23: 425.
19. Wu Y, Xie L. AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput Struct Biotechnol J. 2025; 27: 265-277.
20. Zitnik M, Nguyen F, Wang B, et al. Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities. Int J Inf Fusion. 2019; 50: 71-91.
21. Ivanisevic T, Sewduth RN. Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers. Proteomes. 2023; 11: 34.
22. Mohr AE, Ortega-Santos CP, Whisner CM, et al. Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare. Biomedicines. 2024; 12: 1496.
23. Choi K, Kim JY. Computational approaches to predict the toxicity of bioactive natural products: a mini review of methodologies. Food Sci Biotechnol. 2025; 34: 299-305.
24. Seal S, Mahale M, García-Ortegón M, et al. Machine Learning for Toxicity Prediction Using Chemical Structures: Pillars for Success in the Real World. Chem Res Toxicol. 2025; 38: 759-807.
25. GATC Health Operon Platform. 2026. https://gatchealth.com/operon-platform/
26. Luechtefeld T, Hartung T. Navigating the AI Frontier in Toxicology: Trends, Trust, and Transformation. Curr Environ Health Rep. 2025; 12: 51.
27. Bhattacharya S, Castignani G, Masello L, et al. AI revolution in insurance: bridging research and reality. Front Artif Intell. 2025; 8: 1568266.
28. US Food and Drug Administration. Potential Approaches to Drive Future Integration of New Alternative Methods for Regulatory Decision-Making. 2024.
29. Zhang J, Li H, Zhang Y, et al. Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction. Brief Bioinform. 2025; 26: bbaf533.
30. Cerisier N, Truong E, Watanabe T, et al. Computational prediction of mutagenicity through comprehensive cell painting analysis. Mutagenesis. 2025; 40: 560-574.
31. Nazer LH, Zatarah R, Waldrip S, et al. Bias in artificial intelligence algorithms and recommendations for mitigation. PLOS Digit Health. 2023; 2: e0000278.
32. Norori N, Hu Q, Aellen FM, et al. Addressing bias in big data and AI for health care: A call for open science. Patterns. 2021; 2: 100347.
33. Weiner EB, Dankwa-Mullan I, Nelson WA, et al. Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice. PLOS Digit Health. 2025; 4: e0000810.
34. Lekadir K, Frangi AF, Porras AR, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025; 388: e081554.